Oncology Resource Group experts focus year-round on Emerging Immuno-Oncology to deliver cutting-edge competitive intelligence with unmatched depth, breadth and insight. ONCrg fills a critical gap in the drug industry to rigorously evaluate early stage I-O products that are not clearly being developed in a specific cancer type – before they leap-frog into late stage and/or combination trials that could rapidly change the competitive landscape.
Regina Cheung Ph.D.
Therapy Area Manager
Regina received a Ph.D. in Immunology from Stanford, and B.S. and M.S. degrees in mechanical engineering from Caltech and MIT. She successfully manages multiple hematology areas at ONCrg and brings together strong scientific, analytical, and managerial acumen to lead our I-O efforts.
Stacey McCann, Ph.D.
Stacey received a Ph.D. in Cancer Biology from Stanford University School of Medicine and a B.A. in Microbiology from University of California, Santa Barbara. As a co-founder and senior advisor for all indications, Stacey augments I-O analytics with solid scientific, clinical, and commercial experience.
Nikki Trunnell, Ph.D.
Operations Director, ONCrg
Nikki received a Ph.D. in Cancer Biology from Stanford University School of Medicine and has pioneered multiple new competitive intelligence methodologies at ONCrg. She co-manages the division and plays an instrumental role in I-O scientific and data analytics.
Medical Conference Coverage
In the fast-moving field of Emerging I-O, ONCrg Conference™ reports deliver highly relevant and forward-looking CI from major congresses like AACR, ASCO, ESMO, and SITC. We capture and analyze new clinical and/or preclinical data critical for assessing the potential impact of novel agents and combinations on the future treatment landscape. Our experts personally attend new data presentations, and our syndicated model assures unbiased, comprehensive research while leaving room to customize coverage to a client’s needs.
Expert Advisory Guidance
ONCrg Advisory™ is an open door to ask non-proprietary questions in Emerging I-O and your other subscription areas. Our experts utilize extensive resources and experience to provide extra guidance to inform clients’ key decisions.
Competitive Landscape Analysis
ONCrg Pipeline Strategies™ delivers cutting-edge analysis by mechanism of action for emerging immuno-oncology agents, and includes named drugs in corporate development for unspecified cancer types from preclinical through Phase II. Presentation-style reports are updated quarterly, include pipe- line tables, and provide valuable analytics by subclass and by company.
Monthly Surveillance Reports
ONCrg Sentinel™ provides vigilant monitoring of rapidly evolving scientific, clinical, and commercial activities in Emerging I-O. ONCrg experts identify and analyze events and deliver incisive commentaries to inform subscribers each month and prepare them to respond wisely to ever-changing market conditions.